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Abstract
PARTIAL EXCHANGE TRANSFUSION FOR POLYCYTHEMIA HYPERVISCOSITY
SYNDROME: A 21-YEAR REVIEW Bridget L. Hopewell, Laurie A. Steiner, Richard A.
Ehrenkranz, Matthew J. Bizzarro, and Patrick G. Gallagher. Division of Perinatal
Medicine, Department of Pediatrics, Yale University School of Medicine, New Haven,
Connecticut.
The objective of this study was to examine the use of partial exchange
transfusion (PET) performed for polycythemia hyperviscosity syndrome (PHS) over
time. A retrospective review of 141 infants who received a PET for PHS at Yale-New
Haven Hospital, between 1986-2007 was performed, querying maternal and
neonatal medical records. Patient demographics, risk factors for PHS, indications for
PET, and complications associated with PET and PHS were collected. Overall, there
was no change in the number of PET performed over the study period (r2=0.082,
p=0.192). Eighty-eight percent of patients had at least one risk factor for PHS, most
commonly maternal diabetes. Over time, there was a statistically significant
decrease in maternal diabetes as a risk factor for PHS. Forty percent of patients had
a significant complication attributed to PHS prior to PET. Eighteen percent of
patients had a complication attributed to PET. Life-threatening complications of PHS
or PET were rare. In conclusion, PHS continues to be a problem observed in
neonatal intensive care units, particularly in at-risk populations. PHS and PET are
associated with significant complications. Well designed studies with long-term
follow up are needed to assess the risks and benefits of PET for PHS.
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Introduction
Neonatal polycythemia, a condition in which the percentage of whole blood
occupied by red blood cells is increased, is a diagnosis recognized since antiquity.
The first case is thought to be a red first-born twin recorded in the Bible (Genesis
25:25). Though the condition has been known and recognized, interest has waxed
and waned over the past few decades. There was a flurry of research during the
1970s and 1980s in which animal models were developed, some randomized trials
were undertaken, diagnostic tools were developed and debated, and meetings
abounded with controversy over both the diagnosis and treatment. However, even
though polycythemia is still a common problem, occurring in 1-5.4% of live births,1-6
the literature has remained largely
silent for the past 25 years, leaving

Figure 1: Incidence of venous polycythemia
(hct >/= 65%) by birth weight and
gestational age groupings.1

many of the controversial
questions unexplored.
Because our clinical
observations indicate that
polycythemia continues to be a
common diagnosis and both the
condition and its treatment carry
significant risks of morbidity, we
felt it was time to re-explore this
condition. Our first step in reopening this topic for close examination was to determine how the research from
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the 1970s and 1980s affected the clinical practice here at Yale-New Haven Hospital.
In addition, we wanted to further define the population affected and delineate their
risks for morbidity.
Definitions
Polycythemia and Hyperviscosity are often used interchangeably though they
are not equivalent. Neonatal Polycythemia is significant only because it can lead to
Hyperviscosity syndrome which can lead to alterations in blood flow, sludging of
blood in vessels, clotting or ischemia, leading to end organ damage. An increased
concentration of red blood cells can lead to increased blood viscosity, but this is also
affected by plasma proteins, red cell deformability, hypoxia, and acidosis. The
resulting associated constellation of clinical and laboratory findings is called
polycythemia hyperviscosity syndrome (PHS).7
Fetal Erythropoiesis
Fetal erythropoiesis first begins in the yolk sac until the third to the sixth
month when the liver takes over as the main source of erythropoiesis. Bone
marrow, the major site of adult erythropoiesis, becomes important during the last 3
months of gestation.
The most well-known difference between fetal erythrocytes and adult red
blood cells (RBCs) is that the hemoglobin in fetal erythrocytes has a higher oxygen
affinity which aids in transfer of oxygen from maternal to fetal RBCs. In addition,
they also differ in their membrane proteins, surface antigens, and metabolic enzyme
patterns. They also have a larger mean cell volume and mean cell hematocrit as
compared to adult RBCs. 8
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The fetus adapts to the relatively hypoxic intrauterine environment by
increased erythropoiesis.9 As such, the red blood cell mass of a newborn infant
compared to later infancy, childhood, and adulthood, is significantly increased.
However, this physiologic increase in red blood cell mass can be pathologically
increased by either primary (increased fetal erythropoietic activity) or secondary
(transfusion of RBCs) causes, or reduced plasma volume, leading to polycythemia.10
Blood Viscosity
Viscosity of a newtonian fluid was described by Poiseuille as the ratio of
shear stress to shear rate as such:11
Viscosity= shear stress = (p-p1)r4π
shear rate

8lQ

where p-p1 is the pressure gradient along the blood

Figure 2: Hematocrit vs.
viscosity

vessel, r is the radius, l is the length of the blood vessel
and Q is the blood flow. Figure 2 shows the
relationship of viscosity to hematocrit at high and low
shear rates. 12
However, blood is not a fully Newtonian fluid as
it is a suspension of particles. The viscosity of blood
does not remain constant. It varies with the amount of
constituents, properties of those constituents, as well as features of the
microenvironment of the circulation. Reliable viscometers are in development but
are not currently in use clinical use. 13
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Plasma proteins can contribute to the viscosity of whole blood. Adult
hyperviscosity syndromes can sometimes be attributed to hyperproteinemia states
like diabetes and Waldenstrom’s macroglobulinemia.14,15 However, these are not
conditions observed in the newborn. Increasing fibrinogen in plasma also
correlates to an increase in viscosity.16 As such, the viscosity of plasma in the
newborn is relatively constant at 1.0 to 1.5 centipose which is very near the
viscosity of water, a Newtonian fluid.16,17 Linderkamp’s group saw in their analysis
an overall decrease in plasma viscosity leading to decreased whole-blood viscosity
in pre-term infants. This led them to consider whether polycythemia was less
dangerous in pre-term infants or whether pre-term infants required even lower
viscosity to maintain adequate circulation. 16
The deformability of the RBCs influence viscosity. RBCs in a neonate have
been shown to be more deformable than in an adult, but are also more variable in
shape which leads to a heterogeneous population of RBCs with respect to their
membrane deformability. 18 Aging RBC’s are less deformable than young RBC’s and
this difference in deformability is exaggerated in neonates as compared to adults. 19
The deformability of leukocytes (WBCs) also can influence whole blood
viscosity. Stimulated neutrophils are less deformable than resting neutrophils. 20,21
Inflexible platelets might be suspected to contribute to viscosity. Mean platelet
volume has been shown to correlate with plasma viscosity in cardiac patients. 22
Acidic pH (<7.00) increases blood viscosity.23 This may be due to fluid shifts
into RBCs with decreasing pH. It is hypothesized that along with increasing blood
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volume, asphyxia-induced placental transfusion also decreases pH which
compounds the increase in viscosity. 24
The apparent viscosity of whole blood also varies with the size of the vessels.
Blood flow is high in large vessels and the apparent viscosity is low, while in small
blood vessels the apparent viscosity is high. Changes in the hematocrit cause the
greatest changes in viscosity in small blood vessels. However, it has been known
since the 1930s that viscosity decreases with decreasing size of the capillary25 down
to 3µm.26 This represents high hemodynamic efficiency. The hct of blood does not
affect the viscosity in the capillary which means that in vitro measurements of blood
viscosity may not reflect the viscosity of the blood in the capillary.24 It has been
suggested that viscosity may increase again as the capillary size decreases below 4
mm. The variation in capillary size in different organs may explain the difference in
effects of PHS on
different organs.17 In

Figure 3: Comparison of capillary and venous
hemoglobin in 24 infants

addition, capillary and
venous hemoglobin
determinations are
often quite discordant
which hinders clinical
decision making.
Figure 3 shows
simultaneous capillary and venous hemoglobin determinations for 24 newborn
infants.27
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As blood viscosity is not easily or reliably measured clinically, the hematocrit
is used as an imperfect measure of PHS and is used with clinical impression to
decide on whether or not the child requires treatment. Data has been difficult to
interpret because of variation in studies including source of the blood sample and
age of the infant at the time of measurement.
Oh and Lind also showed in the 1960’s that capillary hematocrit was
consistently 10% higher than simultaneously obtained peripheral venous samples.28
Ramamurthy showed that 80% of infants with an umbilical vein hct >/= 63% have
viscosity greater than three standard deviations above the mean and 94% of
neonates with an umbilical vein hct <63% had viscosity in the normal range.
However, capillary hct, which is usually the first measured in an infant had no
significant correlation between peripheral vein hct or umbilical vein hct. 2 The ideal
measurement would be the in vivo viscosity of blood in arterioles, venules, and
capillaries of key organs,2 but as this is not accessible, we strive for something that
will best correlate. Commonly, a hematocrit of 65% or greater has been used to
define polycythemia.
The timing of the blood sample of the hct is important and can influence
diagnosis because from birth to 6-12 hours of age, shifts in body water increase the
hct, and then decrease the hct similar to the value at birth by about 24 hours. 2,29
Hemodynamics
Signs and symptoms of PHS are believed to be from disturbances in blood
flow in different organs, and thus the hemodynamics have been examined in order
to explain the difference in the effects of PHS on different organ systems. There has
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been no comprehensive study done on the hemodynamics of PHS and much is still
unclear.
With regards to the cardiovascular system, it has been observed in dog
models that there is a decrease in cardiac output with relatively little change in
oxygen transport or delivery. It has also been shown to increase pulmonary
resistance and slightly increase systemic resistance, as well as decrease myocardial
blood flow.30,31 These results have been substantiated in infants as well and the
decreased cardiac output appears to be mostly a result of reduction of heart rate
with possible reduction in stroke volume. 32,33 Fouron and Herbert used a lamb
model to show that pulmonary resistance increases more than systemic resistance.
They then showed that with a hct above 70%, the pulmonary and systemic
resistance were the same. This also reversed the direction of blood flow through the
patent ductus arteriosus. 34
Boehm et. al found that with increasing hematocrit, bile acid concentration in
serum increased and trypsin and lipase activity in duodenal juice was decreased.
These findings were greatest in the asymptomatic infants not treated with PET vs.
symptomatic infants that were treated. 35 The authors warn that managing these
infants nutritionally could be more difficult.
Renal hemodynamics have been examined. In hypervolemic polycythemia
caused by delayed cord clamping, it was shown that there was higher renal blood
flow, greater GFR and greater urine output.36 However, in a puppy model of
normovolemic polycythemia, it was found that while renal blood flow was
preserved, renal plasma flow decreased by 63% and Glomerular Filtration Rate
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(GFR) decreased by 53% resulting in significantly decreased urine output as well as
electrolyte excretion.

36

It has been hypothesized that the difference between these

studies is that both volume status and hct affect renal hemodynamics. 24 Another
study showed infants with PHS had decreased GFR, urine output, and sodium
excretion which was ameliorated by PET. 37
Whether peripheral circulation in the feet of infants with PHS is affected is
not clear. Some studies show no effect on peripheral circulation,38 while others
show that at a given blood volume, an increase in viscosity decreases peripheral
circulation.39 One study showed a decrease in peripheral blood flow which
normalized with PET. However, the infants were neither hypoxic nor hypercarbic
before or after the exchange.40
Doppler studies of cerebral circulation have shown that polycythemic infants
have a significant reduction in cerebral blood flow velocity compared with similar
term infants with normal hematocrits and blood viscosity values. The velocity of the
blood flow also improved after PET in this study. 41 In a newborn lamb model with
induced polycythemia, the same group demonstrated that in polycythemic lambs,
the arterial oxygen content was increased. When the arterial oxygen content was
reduced but the lamb remained polycythemic, the cerebral blood flow increased to
baseline values. This led them to suggest that the reduced flow observed may be
caused by an increased oxygen content, rather than increased viscosity.42
Limitations of most animal models are that polycythemia is induced after birth,
rather than as a result of a hostile uterine environment.
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Symptoms
Symptoms of polycythemia-hyperviscosity are often nonspecific. Many of the
symptoms of PHS can also be attributed to other perinatal problems such as
asphyxia or chronic hypoxia and may not be directly caused by PHS. The presence
of symptoms makes the diagnosis more likely, but the absence of symptoms does
not preclude the diagnosis. These symptoms include a ruddy complexion, lethargy,
hypoglycemia, feeding difficulties, hyperbilirubinemia, thrombocytopenia,
respiratory distress, cyanosis and seizures. Often the infants have a reddish-blue
“ruddy” color in spite of a normal PaO2. Major ischemic clotting events resulting in
gangrenous necrosis have also been reported, and were detected antenatally and
thus are resistant to treatment.43 The respiratory distress is hypothesized to be due
to the elevated pulmonary vascular resistance and perhaps increased shunting in
the lungs.
In addition to poor feeding and vomiting which has been reported with PHS,
necrotizing enterocolitis (NEC) has been associated with PHS in several studies.44,45
However, in a population of patients admitted to a newborn special care unit
already at increased risk for developing NEC, it is nearly impossible to attribute the
development of NEC specifically to PHS. Necrotizing enterocolitis could be
hypothesized to be caused by either sludging of blood in vessels from PHS,
disruption of flow from a partial exchange transfusion, or be unrelated due to
significant other risk factors in this patient population. One study in an animal
model showed the incidence of NEC in polycythemic puppies was 58%.46 However,
Black et al47 found that NEC occurred with higher frequency in patients who had
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received an exchange transfusion, and furthermore found that one third of the
infants had pneumatosis intestinalis. Therefore, they argue NEC is caused by the
exchange transfusion rather than hyperviscosity. Large, prospective, randomized
trials are needed to sort out these relative risks of NEC.
Though renal hemodynamics do seem to be affected, acute renal failure is not
seen frequently in infants with PHS, but it has been reported.48 As with necrotizing
enterocolitis, acute renal failure may be multifactorial in origin and whether PHS is
contributory or a confounding variable in cases of asphyxia or other risk factors has
yet to be sorted out.
Hypoglycemia is a common symptom in polycythemia. Rosenkrantz, using
his lamb model, has hypothesized it is due to a reduced plasma volume. 49 Since
glucose is carried in the plasma, as plasma is reduced, so is glucose. Furthermore, as
blood flow is decreased, the extraction of glucose is increased compounding the
problem. Others have suggested that it is due to decreased glucose production
resulting from hyperviscosity, though the mechanism is unclear. 50 Another
hypothesis is that the excess of red blood cells causes excess glycolysis and
increased consumption of glucose by the red blood cells themselves.
Thrombocytopenia, fibrin monomers, and evidence of intravascular
thromboplastic activity have been found in infants with PHS.51 One study found
thrombocytopenia in 20% of infants with PHS, but they all had normal coagulation
findings.6 Mechanisms have not been determined, but a clotting risk is hypothesized
because of normally low antithrombin III levels combined with impairment of the
microcirculation.52 However, low antithrombin levels are also seen in infants who
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have been asphyxiated and it is unknown whether PHS is a confounding variable or
an independent risk factor.
In some studies, polycythemic infants have been reported to have worse
developmental and neurologic outcomes than their non-polycythemic counterparts.
In 1982, Black et al reported 38% incidence of motor and neurologic abnormalities
in the infants with PHS compared to 11% of matched controls. 53 Asymptomatic
infants with polycythemia have been shown to have increased pulmonary resistance
and relative bradycardia which normalized after PET with no change in stroke
volume thereby increasing cardiac output in those infants. 33 In his review,
Rosenkrantz24 summarized the frequency of symptoms in 4 major studies as
follows:
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Table 1: Frequency of Clinical Symptoms Observed in Association with
Polycythemia Investigation
Clinical Symptoms
Gross
Ramamurthy Black
Goldberg
et al54
and Brans2
et al53
et al55
(n=18)
(n=54)
(n=111)
(n=20)
(%)
(%)
(%)
(%)
Cyanosis
89
17
7
Nr
Plethora

83

63

Nr

Nr

Tremulous/jittery

67

13

Nr

Nr

Abnormal EEG

33

Nr

Nr

Nr

Seizures

28

0

0

Nr

Respiratory distress

44

4

10

15

Cardiomegaly

17

Nr

Nr

85

Lethargy/poor

Nr

50

+

55

Hyperbilirubinemia

50

6

Nr

5

Abnormal blood

50

Nr

Nr

Nr

Thrombocytopenia

39

Nr

Nr

25

Hypoglycemia

33

Nr

27

40

Hypocalcemia

6

Nr

Nr

0

feeding

smear

Nr- not reported or examined
+ - greater incidence compared with the control group

Other reported clinical symptoms include irritability, hypotonia, easily
startled, vomiting, hepatomegaly, and jaundice.
Pathogenesis
Many perinatal factors are associated with the development of polycythemia
including conditions of intrauterine transfusion including twin-twin transfusion,
maternal-fetal transfusion, and delayed cord clamping; conditions associated with
increased fetal erythropoiesis such as acute and chronic fetal hypoxia, fetal trisomy,

13
and endocrine abnormalities.24,56,57 In a large series of infants of diabetic mothers,
5% developed polycythemia.58 Causes of primary and secondary neonatal
polycythemia are summarized in Table 2.59
Table 2: Causes of primary and secondary neonatal polycythemia
Causes of Primary Neonatal Polycythemia
Causes of Secondary Neonatal
Polycythemia
Intrauterine hypoxia
Placental insufficiency
Small for gestational age, growth
retardation

Delayed cord clamping

Preeclampsia
Severe maternal heart disease
Maternal smoking
Maternal insulin-dependent diabetes

Twin-to-Twin transfusion

Neonatal thyrotoxicosis

Maternal-fetal transfusion

Congenital adrenal hyperplasia

Dehydration

High-altitude conditions

Perinatal asphyxia

Chromosome abnormalities
Trisomy 13
Trisomy 18
Trisomy 21
Hyperplastic viceromegaly (BeckwithWiedemann syndrome)
Decreased erythrocyte deformability

Fetal hypoxia is thought to contribute to polycythemia in two ways. First, it
can shift blood from the placental circulation to the fetus, resulting in an increase of
both red cell mass and blood volume. Second, hypoxia may contribute to an
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increase in fetal production of erythropoietin which stimulates development of
more red cells by the fetus. Examples of causes of chronic fetal hypoxia include
maternal diabetes, intrauterine growth restriction (IUGR) or small for gestational
age fetus (SGA), preeclampsia, placental insufficiency, neonatal thyrotoxicosis,
maternal smoking, increased fetal metabolism, and living at high altitude.
Smoking is thought to contribute to the development of PHS because of
hypoxia resulting from a nicotine-induced reduction in uteroplacental blood flow as
well as an increasing fetal carboxy-hemoglobin. Hypoxia then is thought to increase
erythropoietin production. In addition, maternal smoking has been shown to
decrease erythrocyte deformability. 60 Awonusonu et al. determined that term
neonates of mothers who smoke during pregnancy require PET approximately two
and a half times as often as term neonates of mothers who do not smoke. 60
Conditions associated with erythrocyte transfusion such as twin-twin
transfusion, maternal-fetal transfusion, and
delayed cord clamping are also associated
with PHS.61,62 The relationship between an
infants blood volume and placental residual
blood volume at various times of cord
clamping has been known since 1969 as
shown in Figure 4.61 One study showed
14% of infants delivered outside the
hospital developed polycythemia.63

Figure 4: Infant and placental blood
volume vs. time of cord clamping.
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In addition, high altitude is associated with a higher incidence of
polycythemia, presumably owing to the decreased partial pressure of oxygen. It has
been shown that the incidence of polycythemia in Denver, CO at 1610m above sea
level was twice that at
sea level in Virginia. 1,3
Figure 5 shows a

Figure 5: Proposed schematic representation of the
etiology and pathogenesis of hyperviscosity in the
neonate

proposed schema for
the etiology and
pathogenesis of
symptomatic
hyperviscosity states in
the neonate (RBC, red
blood cells).54
Complications
Table 3: Complications associated with neonatal Polycythemia
Complications Associated with Neonatal Polycythemia
Respiratory distress syndrome
Congestive heart failure
Convulsions
Peripheral gangrene
Priapism
Necrotizing enterocolitis
Ileus
Acute renal failure
Abnormal electroencephalographic pattern

16

Treatment
To improve clinical symptoms and potentially improve neurologic outcome,
isovolemic hemodilution, often called partial exchange transfusion (PET) has been
used to reduce the hematocrit. A hematocrit of 60% is the goal of most PET. The
blood volume is calculated by this formula:
(Observed hematocrit – Desired hematocrit [60%])
Observed Hematocrit
The blood volume in the newborn infant is estimated at 80-100 mL/kg body weight.
The usual process consists of attaching an empty syringe to the umbilical vein
catheter and 5-20mL aliquots are withdrawn. Then, another syringe with saline,
Ringer’s Lactate, or plasma is infused at the same time or just after. After each
aliquot, a rest period of 5-10 minutes is taken in which the infant’s vital signs and
clinical symptoms are monitored for any complications. The last aliquot drawn is
usually sent for a CBC. No studies have shown an advantage for either fresh frozen
plasma, albumin, or crystalloid solutions, however with the risk of infection from
plasma, most physicians opt for crystalloid solutions, though it requires monitoring
of electrolyte status.
The rationale for PET is that reducing presumed hyperviscosity decreases
vascular resistance, improves perfusion, and limits end organ damage, thereby
preventing or ameliorating complications of PHS.32,41,64,65 PET may lead to
improvement in symptomatology, such as cyanosis, hypoglycemia,
thrombocytopenia, and cardiac function in the short term.6,33,66-68 PET has also been
shown to increase skin capillary blood flow velocity in vivo especially when
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performed shortly after birth, which is hypothesized to be reflective of other
internal organ capillary blood flow.65 Interestingly, in the study of cerebral blood
flow velocity which found the flow velocity was slower in infants with PHS than in
nonpolycythemic infants, the polycythemic infants showed an increase in blood flow
velocity and a reduction in vascular resistance after being treated with PET.41
However, even with this evidence of immediate improvement, PET has not been
shown to improve long term developmental outcomes in infants with PHS.66,67,69,70
One study showed that for the first two weeks of life, infants treated with PET for
PHS were less irritable, more alert and more easily consoled, but neonatal problems
were not predictive of neurologic outcome at 8 months.55 In addition, one
prospective randomized trial in 1985 showed an increase in abdominal distension
and bloody emesis and bloody stools in hyperviscous patients receiving PET
compared to hyperviscous patients receiving only symptomatic care.47 The lack of
improvement in long term neurologic outcomes has caused many to question the
utility of this procedure 71 in light of possible complications that have not been fully
defined.
Alternative treatments undertaken include watchful waiting, or increased
fluid intake delivered enterally usually by gavage feeding, or parenterally.
The American Academy of Pediatrics guidelines for PET in treatment of PHS
are vague: “The accepted treatment of polycythemia is PET. However, there is no
evidence that exchange transfusion affects long-term outcome.72 In the past 20
years, there have been no studies in the English literature assessing the frequency
with which PET for PHS is performed, the patient population undergoing PET, the
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indications used for initiating PET, and the risks associated with PET. Based on our
longitudinal clinical observations, we hypothesized the following: PHS remains a
common condition in neonatal intensive care units; PET continues to be used in the
treatment of PHS; and both PHS and PET may be associated with neonatal
morbidity. To address these hypotheses, we examined the frequency, indications,
and complications of PET performed for PHS over the past 22 years at a single
institution.
We hope that our study will spur interest in designing controlled studies that
will be more helpful in defining which infants will benefit from PET for PHS. We
also hope it will remind physicians that even procedures that have been done
frequently have risks and help them weigh risks and benefits in their clinical
decision making.
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Hypotheses
Based on review of the literature and the authors’ experience in the Yale-New Haven
Children’s Hospital Newborn Special Care Unit, we hypothesize that PHS remains a
common condition in neonatal intensive care units. We also hypothesize that PET
continues to be used in the treatment of PHS. We further hypothesize that both PHS
and PET may be associated with neonatal morbidity.

Specific Aims
To address our hypotheses, we have developed these specific aims:
1. Determine frequency of PET for PHS over 21 years at a single institution
2. Evaluate demographic information of patients receiving PET
3. Examine risk factors for developing PHS which necessitates PET
4. Compare recorded indications for PET with recommended indications
5. Examine complications attributable to PHS and/or PET
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Patients and Methods
Infants who were long-term admissions (>24 hours) to the Newborn Special
Care Unit (NBSCU) at Yale New Haven Children’s Hospital (YNHCH) from January 1,
1986, through December 31, 2007, and received PET for PHS shortly after birth
were included. Neonates who received a PET for anemia or a double volume
exchange transfusion for any cause were excluded. One infant with iatrogenic
polycythemia was also excluded. Charts from 141 infants who met criteria were
reviewed. During the entire study period, the NBSCU at Yale New Haven Children’s
Hospital was under the same leadership of Dr. Ian Gross and Dr. Richard
Ehrenkranz.
Data collection included incidence of PET, patient and maternal
demographics, known or suspected risk factors for developing PHS, physician
recorded indication for PET, laboratory evaluation surrounding PET, complications
possibly related to PHS, complications possibly related to PET, and comorbidities of
patients receiving PET. In accordance with AAP Guidelines,72 asymptomatic patients
were not screened for polycythemia. Blood viscosity was not measured. Data were
collected in a de-identified manner using pre-designed data collection sheets and
entered into a Microsoft Access Database for collection, review, and analysis.
In order to conduct longitudinal comparison, groups were divided into two
time periods. The early time period was January 1, 1986-December 31, 1996 and the
later time period was January 1, 1997-December 31, 2007. These time periods were
chosen as representative samples of obstetric practice, with the mid 1990’s
representing a time demarking the widespread adoption of numerous advances in
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prenatal care including ultrasound, Doppler techniques, fetal heart rate monitoring,
cordocentesis, and management of the diabetic pregnancy.73,74 These changes were
summarized in the review by Battaglia and Marconi in 1997 on “the new
obstetrics.”73
Risk Factors for Polycythemia Hyperviscosity Syndrome
Mother and infants were assessed for the following risk factors for PHS:
maternal diabetes, maternal hyperthyroidism, maternal smoking, maternal ethanol
use, maternal substance abuse, maternal hypertension, pregnancy-induced
hypertension, preeclampsia, intrauterine growth restriction, twin-twin transfusion
syndrome, fetal trisomy or other genetic syndromes including BeckwithWeidemann syndrome, maternal fetal transfusion, delivery outside labor and
delivery, perinatal asphyxia, delayed cord clamping, nuchal cord, cord stripping,
neonatal hypothyroidism, and congenital adrenal hyperplasia.58,60,63,75-81 The
diagnosis of intrauterine growth restriction was assigned using the criteria of
Alexander et al.82
Indications for Partial Exchange Transfusion
Indications for PET during the study period were: 1) hematocrit of 70% or
above with or without symptoms attributable to PHS; 2) hematocrit of 65% or
above with symptoms attributable to PHS or; 3) at the discretion of the attending
physician because of symptoms attributable to PHS independent of the
hematocrit.2,83 Findings attributable to PHS included plethora, tachypnea, cyanosis,
respiratory distress, feeding intolerance, and neurologic symptoms such as
tremulousness, jitteriness, lethargy, hypoglycemia, or thrombocytopenia. Data was
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extracted from physician procedure notes to determine whether each patient was
symptomatic. There was a significant variation in whether capillary, peripheral
venous or umbilical venous hct was used in determining whether the child should
receive PET.
During the entire 22 year study period, the protocol for partial exchange
transfusion was the following: An umbilical venous catheter (UVC) was placed in a
low lying position and a peripheral intravenous catheter (PIV) was inserted. An
infant’s total blood volume was assumed to be 85cc/kg body weight. The volume of
exchange, calculated as blood volume x (observed hematocrit – desired
hematocrit)/observed hematocrit, was removed via the UVC while infusing the
same volume of normal saline via either the PIV or an umbilical line. This technique,
performed over an approximately 15 minute period, allows the patient to maintain
euvolemia during the entire PET. Upon completion, the UVC was flushed with
normal saline and removed unless there are other indications for its continued use.
Ten percent dextrose was infused via the PIV for at least the next 6 hours while the
patient receives no enteral feeds.
Significant Complications of Polycythemia Hyperviscosity Syndrome or Partial
Exchange Transfusion
Complications that were possibly related to PHS or PET were analyzed. PHSrelated complications were defined as any known complication of PHS present prior
to PET. PET-related complications were defined as any complication, not present
before PET, which occurred within 7 days after the PET. However, in delayed-type
complications like NEC, it was impossible to attribute it to either PET or PHS, and
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was counted as a possible complication in both. Complications of PHS or PET were
defined as follows:
Apnea: Cessation of respirations for > 20 seconds
Bradycardia: Sustained heart rate < 100 bpm
Tachycardia: Sustained heart rate > 180 bpm
Seizures: Clinical evidence of seizure-like activity treated with anti-seizure
medication or EEG-documented seizures
Symptomatic Hypotension: Decline in blood pressure requiring treatment with
intravenous fluids or medication
Pulmonary Hypertension: Respiratory distress with evidence of elevated right heart
pressures by echocardiography or significant variation in pre- and post-ductal SpO2
NEC: Modified Bell’s criteria > stage 2a4,84-86
Renal Failure: Urine output < 1 cc/kg/hr for > 24 hours or serum creatinine
concentration >1.5 mg/dL
Thrombotic or Ischemic Event: Significant disruption of blood flow due to vessel
occlusion from thrombus diagnosed by Doppler ultrasound, contrast angiography,
or magnetic resonance angiography
Catheter Malfunction: Catheter thrombosis, rupture or dysfunction
Severe thrombocytopenia: Platelet count < 50,000/mm3
Hypoglycemia: Blood glucose < 50mg/dL
Hypocalcemia: Serum calcium < 8.0mg/dL or plasma ionized calcium < 3.5mg/dL
Hyperbilirubinemia: elevation of indirect bilirubin requiring treatment with
phototherapy or double-volume exchange transfusion without other known causes
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Intracranial Hemorrhage: Intracranial detected by ultrasound, computerized
tomography or magnetic resonance imaging of the head
PET-Related Mortality: PET-related mortality was defined as any death which was
directly related to the PET and occurred within 7 days after the exchange.
Statistical analysis
The SPSS v13.0 statistical software package (SPSS Inc., Chicago, IL) and
GraphPad Prism 3.0 (GraphPad Software, Inc., San Diego, CA) were utilized for data
analyses. Continuous data were compared using the Student t comparison of means.
Dichotomous data were compared using a Pearson’s chi-square analysis or Fisher’s
exact test when at least one cell contained a value <5. Trends were analyzed using
linear regression analysis. A p-value of <0.05 was considered statistically significant.
Infant Comorbidities
Significant comorbidities including congenital heart disease, respiratory
disease, genetic syndromes, sepsis not related to PHS or PET, IVH, renal disease or
other significant morbidities were also collected.
Laboratory Data
Laboratory data were also collected including pre- and post-exchange
hematocrit, hemoglobin, and platelet count.
Human Subject Protection
This study was approved by the Human Investigation Committee of the Yale
University School of Medicine.
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Statement of the responsibilities of the medical student for which this thesis is
submitted
Bridget Hopewell was responsible for requesting charts from medical
records after a list of patients was generated from a database by another author.
She then reviewed all charts and collected data. All questions or concerns about
individual charts were presented to other authors for verification and clarification.
Ms. Hopewell entered all data into the Microsoft Access Database and together with
Duncan Hopewell queried the data to make all reports, tables, and figures except for
Figure 6 which required advanced statistical software and data on admissions that
was queried and analyzed by another author.
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Results
From January 1, 1986 to December 31, 2007, there were 108,147 live births
(mean 4915+351 births/year) at Yale New-Haven Children’s Hospital (YNHCH) and
18,117 long term admissions, inborn and outborn, (mean 823+56 long term
admissions/year) to the YNHCH Newborn Special Care Unit (NBSCU). PET was
performed in 169 infants. Twenty eight infants were excluded; 25 who underwent
PET for anemia-related conditions or iatrogenic polycythemia, and 3 with
incomplete medical records. The study group was composed of 141 patients who
underwent PET for PHS shortly after birth.
Patient characteristics are shown in Table 4. One hundred nine infants were
singletons. Mean gestational age was 37.3 weeks (range 24-42 weeks). Mean birth
weight was 2788g (range 680-4980g). Male:female ratio was 1:1. Most patients had
generally normal Apgar scores. PET was mostly performed on Caucasian neonates,
followed by Hispanic neonates and Black neonates. Neonates were slightly smaller
in weight in the later time period vs. the early time period. There was a smaller
percentage of Caucasian neonates in the later period. There was also a decrease in
the percentage of singletons and an increase in the percentage of multiple gestation
patients receiving PET. Finally, there was an increase in the percentage of patients
born by caesarian section receiving PET. Over the 22 year period, the number of
PET/year/1000 live births was essentially unchanged. A slight downward trend was
not statistically significant (r2 = 0.082, p=0.192, Figure 6). PET was almost always
performed in the first twenty-four hours of life. The median time to the first
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procedure was 9.0 hours. The mean number of hours to the PET, 21.5, was skewed
to the right because of some outliers.
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Table 4: Perinatal Characteristics and Demographic Factors
Perinatal
All
1986-1996
Characteristics

1997-2007

patients

N=82

N=59

Gestational

37.3 ± 3.1

37.8 ± 2.5

36.6 ± 3.6

Age (weeks)*

(n=138)

(n=80)

(n=58)

Birth weight

2788 ± 871

(grams)

(n=139)

2977±844

2524±847

(n=81)

(n=58)

16 (11%)

10 (12%)

6 (10%)

11 (8%)

8 (10%)

3 (5%)

Male

70 (50%)

42 (51%)

28 (47%)

Female

71 (50%)

40 (49%)

31 (53%)

White

83 (59%)

54 (66%)

29 (49%)

Black

11 (8%)

9 (11%)

2 (3%)

Hispanic

16 (11%)

10 (12%)

6 (10%)

Asian

2 (1%)

0 (0%)

2 (3%)

Other

3 (2%)

2 (3%)

1 (2%)

Not reported

24 (17%)

5 (6%)

19 (32%)

Singleton

109 (77%)

69 (84%)

40 (68%)

Twin A

7 (5%)

3 (4%)

4 (7%)

Twin B

18 (13%)

8 (10%)

10 (17%)

Triplet A

1 (1%)

0 (0%)

1 (2%)

Triplet C

4 (3%)

1 (1%)

3 (5%)

Not Reported

2 (1%)

1 (1%)

1 (2%)

Vaginal

96 (68%)

62 (76%)

34 (58%)

C-Section

45 (32%)

20 (24%)

25 (42%)

1 minute
Apgar ≤5**
5 minute
Apgar ≤7 **
Demographics**
Sex

Race

Birth Order

Mode of Delivery

* Mean ± Standard Deviation
** Number (Percent)
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Figure 6: Partial Exchange Transfusions Over Time.

*r2=0.082, p=0.192

Several risk factors for neonatal polycythemia have been reported. Each
patient’s chart was reviewed to determine which risk factors most commonly
resulted in PHS requring PET at YNHH. The majority of patients (88%) had at least
one risk factor for PHS (Table 5), with the most common risk factor being maternal
diabetes. Other common risk factors included maternal hypertension, fetal trisomy,
and unsupervised delivery (Table 5). Fifty four neonates (38%) had more than one
risk factor. Comparing risk factors between the early and late time periods, there
was a statistically significant decrease in maternal diabetes (p<0.01) in the later,
more recent time period.
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Table 5. Perinatal Risk Factors.
Perinatal Risk Factor*

Number

1986-1996

1997-2007

(Percent)

(n=82)

(n=59)

Maternal Diabetes

39 (28%)

29 (35%)

10 (17%)**

Maternal Hypertension

25 (18%)

14(17%)

11 (19%)

Maternal Substance abuse

16 (11%)

9 (11%)

7 (12%)

Maternal Hypothyroidism

2 (1%)

0 (0%)

2 (3%)

Placental Insufficiency

6 (4%)

0 (0%)

6 (10%)

Twin-Twin Transfusion

10 (7%)

4 (5%)

6 (10%)

Nuchal Cord

15 (11%)

11 (13%)

4 (7%)

Unintended Delivery

14 (10%)

8 (10%)

6 (10%)

48 (34%)

23 (28%)

25 (42%)

19 (13%)

11 (13%)

8 (14%)

Outside Delivery Room/
Delayed Cord Clamping
Intrauterine Growth
Restriction
Fetal Genetic Syndrome
Trisomy 21

15

8

7

Trisomy 13

1

1

0

2

1

Other

3

Other Risk Factors

4 (3%)

4 (5%)

0 (0%)

Any Perinatal Risk Factor

121 (86%)

72 (88%)

49 (83%)

* Number (Percent)
**p<0.01

There are no clear, evidence-based guidelines for when to initiate PET.
Similar to other centers, in our institution, a PET is initiated for a hematocrit > 70%
in the asymptomatic patient or for a hematocrit > 65% with symptoms attributed to
PHS.20 During the study period, 50% of patients (n=71) received a PET because of a
hematocrit > 70%. Thirty nine percent (n=55) received a PET because of a
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hematocrit > 65% and symptoms attributed to PHS. The remaining patients (11%)
underwent PET with a hematocrit between 60-65% and symtoms attributed to PHS.
Mean hematocrits before and after PET were 69.7+4.2% and 57.3+5.8%,
respectively. In contrast to previous studies which included mostly asymptomatic
infants, due to our selection bias, the majority of the patients in our series had at
least one clinical sign or symptom attributed to PHS in addition to an elevated
hematocrit prior to PET (Table 6).24 The most common findings were
hypoglycemia, plethora, tachypnea and jitteriness. Because of the three accepted
indications for PET, there was a wide range of hematocrits before and after
transfusion as shown in Figure 7, but the mean hematocrit before transfusion was
69, and the mean hematocrit after transfusion was 58.
Figure 7: Hematocrits before and after PET.
*The mean hematocrit before PET was 69 and the mean hematocrit after PET was 58
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Table 6. Signs and Symptoms Attributed to Polycythemia Hyperviscosity
Syndrome Before Perinatal Partial Exchange Transfusion.
Signs and Symptoms

Number

1986-1996

1997-2007

(Percent)

(n=82)

(n=59)

Hypoglycemia

41 (29%)

24 (29%)

17 (29%)

Plethora

35 (25%)

22 (27%)

13 (22%)

Tachypnea

19 (13%)

5 (6%)

14 (24%)

Jitteriness

18 (13%)

11 (13%)

7 (12%)

Cyanosis

13 (9%)

8 (10%)

5 (8%)

Thrombocytopenia

8 (6%)

3 (4%)

5 (8%)

Hypotonia

6 (4%)

0 (0%)

6 (10%)

Apnea

4 (3%)

2 (2%)

2 (3%)

Feeding intolerance

4 (3%)

2 (2%)

2 (3%)

Lethargy

4 (3%)

3 (4%)

1 (2%)

Other recorded

16 (11%)

3 (4%)

13 (22%)

51 (62%)

45 (76%)

indication
Any sign or symptom 96 (68%)

In addition to the signs and symptoms attributed to PHS described in Table
6, several additional clinically significant complications of PHS have been described.
These include cardiopulmonary and neurologic problems. In our series, over one
third of patients (40%) had significant complications attributed to PHS prior to the
inititation of PET (Table 7) including pulmonary hypertension, necrotizing
enterocolitis, thrombotic/ischemic events, and severe thrombocytopenia.
Hyperbilirubinemia was the most frequent complication (n=41, 29%). As the
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median time from birth to PET was 9 hours, this finding re-enforces the suggestion
that polycythemia can cause clinically significant jaundice, even on day of life one.
Table 7: Complications Attributed to Polycythemia Hyperviscosity Syndrome
Complication

Number

1986-1996

1997-2007

(Percent)

n=82

n=59

Hyperbilirubinemia

41(29%)

26 (32%)

15 (25%)

Pulmonary Hypertension

8 (6%)

4 (5%)

4 (7%)

Necrotizing Enterocolitis

5 (4%)

2 (2%)

3 (5%)

Thrombotic/Ischemic Event

2 (1%)

0 (0%)

2 (3%)

Thrombocytopenia

2 (1%)

0 (0%)

2 (3%)

Any Complication

56 (40%)

32(39%)

24 (41%)

Few studies have examined the complications associated with PET, and those
studies have focused on the GI complications, most notably necrotizing enterocolitis
(NEC). In our study, PET-related complications were common, occurring in 25
patients (18%) (Table 5). The most common were catheter-related complications.
Other life-threating complications of PET were rare, but did occur (including sepsis
and hypotension, Table 8). Similar to previous studies,67 we found an increased
incidence of NEC after PET. Because PHS alone is a risk factor for NEC, it is
impossible to determine if NEC would have occurred if PET had not been carried
out. There were no statistically significant differences in complications between the
two time periods studied.
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Table 8. Complications Attributed to Partial Exchange Transfusion
Complication

Number

1986-1996

1997-2007

(Percent)

n=82

N=59

Catheter Complication

10 (7%)

4 (5%)

6 (10%)

NEC

5 (4%)

2 (2%)

3 (5%)

Thrombocytopenia

8 (6%)

2 (2%)

6 (10%)

Suspected or Proven Sepsis

5 (4%)

5 (6%)

0 (0%)

Hypotension

1 (1%)

1 (1%)

0 (0%)

Any Complication

25 (18%)

8 (10%)

17 (29%)

35

Discussion
These data demonstrate that PET for PHS continues to be a common
procedure at YNHCH, without evidence for decline over two decades, representing
the longest single-center, longitudinal documentation of trends in PET. They also
document that the patient population undergoing PET was generally term neonates
with one or more risk factors for PHS. A large number of patients had clinical
symptoms consistent with PHS prior to PET. Since the AAP recommends against
screening asymptomatic patients for polycythemia,72 our symptomatic patient
population is likely representative of the majority of infants who currently undergo
PET for PHS, yet previous studies of PET for PHS have focused on asymptomatic
infants.66,87
There are no randomized, controlled studies of the efficacy of PET done in
symptomatic infants, and it is difficult to generalize studies of efficacy done on
largely asymptomatic infants to a symptomatic popoulation. Although further
studies of PET in symptomatic patients are necessary to determine whether PET
provides a clinically significant, long term benefit, monitoring of high-risk
populations to identify infants with symptomatic PHS is critical. Multiple studies
have demonstrated that symptomatic patients with PHS are at risk for adverse
neurologic outcomes,53,55,69 highlighting the need for careful developmental followup of these infants even if they do not undergo PET. These data are consistent with
the hypothesis that in some patients, an adverse intrauterine environment or a
significant perinatal event leads to tissue hypoxia, polycythemia, hyperviscosity, and
irreversible tissue damage that would not be ameliorated by PET.7,66,69 Future
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studies to compare infants with PHS caused by an adverse intrauterine environment
leading to hypoxia and tissue damage with infants developing PHS because of a onetime insult at birth like delayed cord clamping may be illuminating.
The literature contains very little information regarding the safety of PET. A
meta-analysis has demonstrated an increased risk of NEC following PET,67 but
studies specifically detailing adverse events related to PET have not been done.
Although the majority of the complications associated with PET in this series were
minor, serious complications were observed. The possiblity of serious
complications from PET supports the practice of not doing PET on asymptomatic
infants, who are unlikely to benefit from the procedure.
The lack of data regarding the risks and benefits of PET makes it difficult to
determine when to initiate a PET and the threshold hematocrit at which to perform
a PET.88 The standard of care in many nurseries, outlined by Linderkamp,20 is to
perform a PET when the venous hematocrit is ≥ 65% in an infant with symptoms of
PHS or when the venous hematocrit is ≥ 70% in an asymptomatic infant, although
there are little data to support this approach. In other institutions, PET is not
performed in asymptomatic neonates until the hematocrit is > 75%. Part of the
controversy over the threshold hematocrit stems from the fact that hematocrit is an
imprecise method of determining blood viscosity and may be a poor indicator of
who needs a PET. Polycythemia and hyperviscosity are not synonymous terms and
many factors in addition to hematocrit, such as plasma proteins, leukocytes,
fibrinogen, platelets, blood pH, and erythrocyte deformability can affect blood
viscosity.16,17,23,24,38,56 Direct measurement of blood viscosity, measured using a
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whole blood viscometer, is often not available in the clinical setting and thus the
hematocrit is used as a surrogate marker. However, hematocrit is an imperfect
measure of viscosity, as not all infants with an elevated hematocrit have increased
blood viscosity.89 Given the risk of complications from both PHS and PET, a more
precise test of blood viscosity is needed to better determine which patients might
benefit from PET.
As risk factors for PHS are diverse and include an unfavorable uterine
environment leading to tissue hypoxia, endocrine abnormalities, genetic
abnormalities as well as transfusion of erythrocytes, it is possible PHS is a more
heterogeneous population. As such, it is currently unclear whether the different risk
factors for developing PHS lead to different outcomes, and would respond
differently to PET. It has been hypothesized that poor developmental outcomes are
more related to a hostile uterine environment which also causes polycythemia, and
thus would not respond to PET.67 Perhaps patients with PHS which develops from a
harsh uterine environment and infants with PHS associated with erythrocyte
transfusion represent separate populations. A meta-analysis showed that delayed
cord clamping by 2 minutes after birth did cause an increase in polycythemia that
appeared to be asymptomatic.76 Our sample sizes were not large enough to
separate and compare these different populations, but it is an area for further study.
Additional factors contributing to the controversy in decision making in PHS
include a lack of standardized diagnostic criteria for PHS, inconsistent study
methodology, and variability in the methodology utilized for PET. Data are not
available to determine whether reducing the hematocrit leads to improvements in
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long term outcome, as well controlled studies comparing long term follow up in
symptomatic and asymptomatic infants treated with PET to those treated
expectantly, are not available.
Our data exemplify the advantages and disadvantages of single-center
observational studies. The longitudinal collection of data over more than two
decades has allowed us to analyze trends in treatment of PHS with PET over time.
Limitations of this study include its retrospective nature, relatively small sample
size, lack of long term developmental follow up data, and a lack of a specific control
group for these patients. We have tried to clearly define complications from PHS and
PET. However, due to the large amount of overlap in symptomatology, it is
impossible to truly define a complication as resulting entirely from PET, as PHS may
have also contributed to its occurrence. It is also possible that complications
attributed to PHS or PET were due to other unknown causes, especially since our
population consisted of complex patients admitted to the NBSCU. It should
therefore be recognized that complications cannot be attributed with absolute
certainty within the limits of this retrospective chart review. Confounding is
therefore possible in our study, and further controlled investigation into
complications could help elucidate the attributable risk of complications specific to
PHS and PET.
We conclude that PHS remains a common problem, particularly in at-risk
populations. Both PHS and PET are associated with clinically significant
complications. Despite its frequency, treatment of PHS with PET remains
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controversial. Additional controlled studies with long term follow up are needed to
assess the benefits of PET for PHS.

40

References
1.
Wirth F, Goldberg K, Lubchenco L. Neonatal hyperviscosity: I. Incidence. Pediatrics 1979;63:8336.
2.
Ramamurthy R, Brans Y. Neonatal polycythemia: I. Criteria for diagnosis and treatment.
Pediatrics 1981;68:168-74.
3.
Stevens K, Wirth F. Incidence of neonatal hyperviscosity at sea level. J Pediatr 1980;97:118-9.
4.
Wiswell T, Cornish J, Northam R. Neonatal polycythemia: frequency of clinical manifestations and
other associated findings. Pediatrics 1986;78:26-30.
5.
Shohat M, Merlob P, Reisner S. Neonatal polycythemia: I. Early diagnosis and incidence relating
to time of sampling. Pediatrics 1984;73:7-10.
6.
Katz J, Rodriguez E, Mandani G, Branson H. Normal coagulation findings, thrombocytopenia, and
peripheral hemoconcentration in neonatal polycythemia. J Pediatr 1982;101:99-102.
7.
Black V. Neonatal hyperviscosity syndromes. Curr Probl Pediatr 1987;17:73-130.
8.
Forestier F, Daffos F, Galactéros F, Bardakjian J, Rainaut M, Beuzard Y. Hematological values of
163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986;20:342-6.
9.
Finne PH, Halvorsen S. Regulation of erythropoiesis in the fetus and newborn. Arch Dis Child
1972;47:683-7.
10.
Wesenberg RL, Rumack CM, Lubchenco LO, Wirth FH, McGuinness GA, Tomlinson AL. Thick blood
syndrome. Radiology 1977;125:181-3.
11.
Poiseuille J. Recherches Expérimentales sur le Mouvement des Liquides dans les Tubes de Très
Petits Diamètres. Hebd Seanc Acad Sci, Paris 1841;11:961-1048.
12.
Phibbs R, ed. Neonatal polycythemia. 16th ed. New York: Appleton-Centry-Crofts; 1997.
13.
Kang YJ, Yoon SY, Lee KH, Yang S. A highly accurate and consistent microfluidic viscometer for
continuous blood viscosity measurement. Artif Organs 2010;34:944-9.
14.
Wells R. Syndromes of hyperviscosity. N Engl J Med 1970;283:183-6.
15.
Somer T, Ditzel J. Clinical and rheological studies in a patient with hyperviscosity syndrome due
to Waldenström's macroglobulinemia. Bibl Haematol 1981:242-6.
16.
Linderkamp O, Versmold H, Riegel K, Betke K. Contributions of red cells and plasma to blood
viscosity in preterm and full-term infants and adults. Pediatrics 1984;74:45-51.
17.
Dintenfass L. Blood viscosity, internal fluidity of the red cell, dynamic coagulation and the critical
capillary radius as factors in the physiology and pathology of circulation and microcirculation. Med J Aust
1968;1:688-96.
18.
Ruef P, Linderkamp O. Deformability and geometry of neonatal erythrocytes with irregular
shapes. Pediatr Res 1999;45:114-9.
19.
Linderkamp O, Wu PY, Meiselman HJ. Deformability of density separated red blood cells in
normal newborn infants and adults. Pediatr Res 1982;16:964-8.
20.
Ruef P, Poeschl JM, Simon C, Altfelder F, Craciun E, Linderkamp O. Effect of activators and the
phosphodiesterase inhibitors pentoxifylline and enoximone on the deformability of neutrophils in
neonates and adults. Acta Paediatr 2004;93:1288-93.
21.
Linderkamp O, Ruef P, Brenner B, Gulbins E, Lang F. Passive deformability of mature, immature,
and active neutrophils in healthy and septicemic neonates. Pediatr Res 1998;44:946-50.
22.
Senen K, Topal E, Kilinc E, et al. Plasma viscosity and mean platelet volume in patients undergoing
coronary angiography. Clin Hemorheol Microcirc 2010;44:35-41.
23.
Rand P, Austin W, Lacombe E, Barker N. pH and blood viscosity. J Appl Physiol 1968;25:550-9.
24.
Rosenkrantz T. Polycythemia and hyperviscosity in the newborn. Semin Thromb Hemost
2003;29:515-27.
25.
Fahraeus R, Lindqvist T. The viscosity of the blood in narrow capillary tubes. Am J Physiol
1931;96:562-8.
26.
Burton AC. Role of geometry, of size and shape, in the microcirculation. Fed Proc 1966;25:175360.

41
27.
OETTINGER L, MILLS WB. Simultaneous capillary and venous hemoglobin determinations in the
newborn infant. J Pediatr 1949;35:362-5.
28.
Oh W, Lind J. Venous and capillary hematocrit in newborn infants and placental transfusion. Acta
Paediatr Scand 1966;55:38-48.
29.
Reisner SH, Mor N, Levy Y, Merlob P. Incidence of neonatal polycythemia. Isr J Med Sci
1983;19:848-9.
30.
LeBlanc MH, Kotagal UR, Kleinman LI. Physiological effects of hypervolemic polycythemia in
newborn dogs. J Appl Physiol 1982;53:865-72.
31.
Surjadhana A, Rouleau J, Boerboom L, Hoffman JI. Myocardial blood flow and its distribution in
anesthetized polycythemic dogs. Circ Res 1978;43:619-31.
32.
Swetnam S, Yabek S, Alverson D. Hemodynamic consequences of neonatal polycythemia. J
Pediatr 1987;110:443-7.
33.
Murphy DJ, Reller M, Meyer R, Kaplan S. Effects of neonatal polycythemia and partial exchange
transfusion on cardiac function: an echocardiographic study. Pediatrics 1985;76:909-13.
34.
Fouron JC, Hébert F. The circulatory effects of hematocrit variations in normovolemic newborn
lambs. J Pediatr 1973;82:995-1003.
35.
Boehm G, Delitzsch AK, Senger H, DelSanto A, Moro G, Minoli I. Postnatal development of liver
and exocrine pancreas in polycythemic newborn infants. J Pediatr Gastroenterol Nutr 1992;15:310-4.
36.
Kotagal UR, Kleinman LI. Effect of acute polycythemia on newborn renal hemodynamics and
function. Pediatr Res 1982;16:148-51.
37.
Aperia A, Bergqvist G, Broberger O, Thodenius K, Zetterström R. Renal function in newborn
infants with high hematocrit values before and after isovolemic haemodilution. Acta Paediatr Scand
1974;63:878-84.
38.
Bergqvist G, Zetterström R. Blood viscosity and peripheral circulation in newborn infants. A study
on resting flow. Acta Paediatr Scand 1974;63:865-8.
39.
Linderkamp O, Strohhacker I, Versmold HT, Klose H, Riegel KP, Betke K. Peripheral circulation in
the newborn: interaction of peripheral blood flow, blood pressure, blood volume, and blood viscosity. Eur
J Pediatr 1978;129:73-81.
40.
Waffarn F, Tolle CD, Huxtable RF. Effects of polycythemia and hyperviscosity on cutaneous blood
flow and transcutaneous PO2 and PCO2 in the neonate. Pediatrics 1984;74:389-94.
41.
Rosenkrantz T, Oh W. Cerebral blood flow velocity in infants with polycythemia and
hyperviscosity: effects of partial exchange transfusion with Plasmanate. J Pediatr 1982;101:94-8.
42.
Rosenkrantz TS, Stonestreet BS, Hansen NB, Nowicki P, Oh W. Cerebral blood flow in the
newborn lamb with polycythemia and hyperviscosity. J Pediatr 1984;104:276-80.
43.
Scott F, Evans N. Distal gangrene in a polycythemic recipient fetus in twin-twin transfusion.
Obstet Gynecol 1995;86:677-9.
44.
Leake RD, Thanopoulos B, Nieberg R. Hyperviscosity syndrome associated with necrotizing
enterocolitis. Am J Dis Child 1975;129:1192-4.
45.
Hakanson DO, Oh W. Necrotizing enterocolitis and hyperviscosity in the newborn infant. J Pediatr
1977;90:458-61.
46.
LeBlanc MH, D'Cruz C, Pate K. Necrotizing enterocolitis can be caused by polycythemic
hyperviscosity in the newborn dog. J Pediatr 1984;105:804-9.
47.
Black V, Rumack C, Lubchenco L, Koops B. Gastrointestinal injury in polycythemic term infants.
Pediatrics 1985;76:225-31.
48.
Herson VC, Raye JR, Rowe JC, Philipps AF. Acute renal failure associated with polycythemia in a
neonate. J Pediatr 1982;100:137-9.
49.
Rosenkrantz TS, Philipps AF, Knox I, et al. Regulation of cerebral glucose metabolism in normal
and polycythemic newborn lambs. J Cereb Blood Flow Metab 1992;12:856-65.
50.
Creswell JS, Warburton D, Susa JB, Cowett RM, Oh W. Hyperviscosity in the newborn lamb
produces pertubation in glucose homeostasis. Pediatr Res 1981;15:1348-50.
51.
Rivers RP. Coagulation changes associated with a high haematocrit in the newborn infant. Acta
Paediatr Scand 1975;64:449-56.

42
52.
Henriksson P. Hyperviscosity of the blood and haemostasis in the newborn infant. Acta Paediatr
Scand 1979;68:701-4.
53.
Black V, Lubchenco L, Luckey D, et al. Developmental and neurologic sequelae of neonatal
hyperviscosity syndrome. Pediatrics 1982;69:426-31.
54.
Gross GP, Hathaway WE, McGaughey HR. Hyperviscosity in the neonate. J Pediatr 1973;82:100412.
55.
Goldberg K, Wirth F, Hathaway W, et al. Neonatal hyperviscosity. II. Effect of partial plasma
exchange transfusion. Pediatrics 1982;69:419-25.
56.
Sarkar S, Rosenkrantz T. Neonatal polycythemia and hyperviscosity. Semin Fetal Neonatal Med
2008;13:248-55.
57.
Wiedmeier S, Henry E, Christensen R. Hematological abnormalities during the first week of life
among neonates with trisomy 18 and trisomy 13: data from a multi-hospital healthcare system. Am J Med
Genet A 2008;146:312-20.
58.
Cordero L, Treuer S, Landon M, Gabbe S. Management of infants of diabetic mothers. Arch
Pediatr Adolesc Med 1998;152:249-54.
59.
Lindermann R, Haga P. evaluation and Treatment of Polycythemia in the Neonate. 1st ed.
Philadelphia: W.B. Saunders; 2000.
60.
Awonusonu F, Pauly T, Hutchison A. Maternal smoking and partial exchange transfusion for
neonatal polycythemia. Am J Perinatol 2002;19:349-54.
61.
Yao A, Moinian M, Lind J. Distribution of blood between infant and placenta after birth. Lancet
1969;2:871-3.
62.
Lopriore E, Oepkes D, van den Wijngaard J, van Gemert M, Middeldorp J, Vandenbussche F. Twin
anemia-polycythemia sequence (TAPS) without a cause. Prenat Diagn 2008;28:559-60.
63.
Bateman D, O'Bryan L, Nicholas S, Heagarty M. Outcome of unattended out-of-hospital births in
Harlem. Arch Pediatr Adolesc Med 1994;148:147-52.
64.
Bada H, Korones S, Kolni H, et al. Partial plasma exchange transfusion improves cerebral
hemodynamics in symptomatic neonatal polycythemia. Am J Med Sci 1986;291:157-63.
65.
Norman M, Fagrell B, Herin P. Effects of neonatal polycythemia and hemodilution on capillary
perfusion. J Pediatr 1992;121:103-8.
66.
Bada H, Korones S, Pourcyrous M, et al. Asymptomatic syndrome of polycythemic hyperviscosity:
effect of partial plasma exchange transfusion. J Pediatr 1992;120:579-85.
67.
Dempsey E, Barrington K. Short and long term outcomes following partial exchange transfusion
in the polycythaemic newborn: a systematic review. Arch Dis Child Fetal Neonatal Ed 2006;91:F2-6.
68.
Murphy DJ, Reller M, Meyer R, Kaplan S. Left ventricular function in normal newborn infants and
asymptomatic infants with neonatal polycythemia. Am Heart J 1986;112:542-7.
69.
Black V, Lubchenco L, Koops B, Poland R, Powell D. Neonatal hyperviscosity: randomized study of
effect of partial plasma exchange transfusion on long-term outcome. Pediatrics 1985;75:1048-53.
70.
Ozek E, Soll R, Schimmel M. Partial exchange transfusion to prevent neurodevelopmental
disability in infants with polycythemia. Cochrane Database Syst Rev 2010:CD005089.
71.
Werner E. Neonatal polycythemia and hyperviscosity. Clin Perinatol 1995;22:693-710.
72.
American Academy of Pediatrics Committee on Fetus and Newborn: Routine evaluation of blood
pressure, hematocrit, and glucose in newborns. Pediatrics 1993;92:474-6.
73.
Battaglia F, Marconi A. The new obstetrics: its integration into neonatal clinical practise, teaching
and research. J Perinat Med 1997;25:399-405.
74.
Johnstone F, Lindsay R, Steel J. Type 1 diabetes and pregnancy: trends in birth weight over 40
years at a single clinic. Obstet Gynecol 2006;107:1297-302.
75.
Mimouni F, Miodovnik M, Siddiqi T, Butler J, Holroyde J, Tsang R. Neonatal polycythemia in
infants of insulin-dependent diabetic mothers. Obstet Gynecol 1986;68:370-2.
76.
Hutton E, Hassan E. Late vs early clamping of the umbilical cord in full-term neonates: systematic
review and meta-analysis of controlled trials. JAMA 2007;297:1241-52.
77.
Kugelman A, Borenstein-Levin L, Riskin A, et al. Immediate versus delayed umbilical cord
clamping in premature neonates born < 35 weeks: a prospective, randomized, controlled study. Am J
Perinatol 2007;24:307-15.

43
78.
Miller M, Cosgriff J. Hematological abnormalities in newborn infants with Down syndrome. Am J
Med Genet 1983;16:173-7.
79.
Rosenberg A. The IUGR newborn. Semin Perinatol 2008;32:219-24.
80.
USHER R, SHEPHARD M, LIND J. THE BLOOD VOLUME OF THE NEWBORN INFANT AND
PLACENTAL TRANSFUSION. Acta Paediatr 1963;52:497-512.
81.
Weinblatt M, Fort P, Kochen J, DiMayio M. Polycythemia in hypothyroid infants. Am J Dis Child
1987;141:1121-3.
82.
Alexander G, Himes J, Kaufman R, Mor J, Kogan M. A United States national reference for fetal
growth. Obstet Gynecol 1996;87:163-8.
83.
Dempsey E, Barrington K. Crystalloid or colloid for partial exchange transfusion in neonatal
polycythemia: a systematic review and meta-analysis. Acta Paediatr 2005;94:1650-5.
84.
Lambert D, Christensen R, Henry E, et al. Necrotizing enterocolitis in term neonates: data from a
multihospital health-care system. J Perinatol 2007;27:437-43.
85.
Wiswell T, Robertson C, Jones T, Tuttle D. Necrotizing enterocolitis in full-term infants. A casecontrol study. Am J Dis Child 1988;142:532-5.
86.
Walsh M, Kliegman R, Fanaroff A. Necrotizing enterocolitis: a practitioner's perspective. Pediatr
Rev 1988;9:219-26.
87.
Ratrisawadi V, Plubrukarn R, Trakulchang K, Puapondh Y. Developmental outcome of infants with
neonatal polycythemia. J Med Assoc Thai 1994;77:76-80.
88.
Wong W, Fok T, Lee C, et al. Randomised controlled trial: comparison of colloid or crystalloid for
partial exchange transfusion for treatment of neonatal polycythaemia. Arch Dis Child Fetal Neonatal Ed
1997;77:F115-8.
89.
Drew J, Guaran R, Grauer S, Hobbs J. Cord whole blood hyperviscosity: measurement, definition,
incidence and clinical features. J Paediatr Child Health 1991;27:363-5.

